Our Story

Christopher Smith

Partner - Melbourne

Chris joined Brandon Capital in 2012.

Before joining Brandon Capital Chris was a Business Development Manager with CSL, Australia’s largest pharmaceutical company. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. As a consequence Chris has extensive experience with both in-licensing and out-licensing therapeutic drugs and R&D enabling platforms. Earlier Chris spent three years as a postdoctoral scientist at The University of Cambridge, UK.

Chris is currently a director of; Aravax, Denteric, Ena Respiratory, MycRx, Q-Sera and Axelia Oncology.

Chris has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Immunology conducted at the Walter and Eliza Hall Institute, and an MBA, specialising in innovation and entrepreneurship, from the University of Cambridge. Chris is a graduate of the Australian Institute of Company Directors.

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.